In Indonesia, a patient with terminal cancer often faces a cruel choice: endure excruciating pain or risk legal trouble to find relief. Despite being a signatory to international treaties that guarantee access to essential medicines, the country’s medical opioid consumption is among the lowest in the world. The culprit? A pervasive fear—among doctors, regulators, and the public—that these drugs are more dangerous than the pain they are designed to treat.
This fear is not unfounded, given Indonesia’s strict narcotics laws and aggressive anti-drug campaigns. But it has created a tragic imbalance: while the world’s high-income countries consume the vast majority of medical opioids, low- and middle-income nations like Indonesia account for a tiny fraction, leaving millions to suffer unnecessarily. This article explores how fear shapes opioid policy and patient access, and why breaking this cycle is a moral and medical imperative.
The Global Access Gap: A Tale of Two Worlds
The World Health Organization (WHO) lists morphine, codeine, and other medical opioids as essential medicines for managing pain, especially in cancer and palliative care. Yet, about 80% of the world’s population lives in countries with low or non-existent access to these drugs. High-income countries, with just a fraction of the global population, consume the overwhelming majority of medical opioids. Low- and middle-income countries (LMICs), which bear a disproportionate share of the global disease burden—including cancer, HIV/AIDS, and injuries—are left with almost nothing.
Indonesia is a stark example. Its medical opioid consumption is often cited as less than 1% of what would be expected for its population size and disease burden. This is not because Indonesians don’t feel pain; it’s because the system makes it nearly impossible to get relief.
Indonesia’s Legal Labyrinth: Control Over Care
Indonesia’s narcotics laws are among the strictest in the world. Law No. 35 of 2009 criminalizes unauthorized possession and use, with penalties ranging from long prison sentences to the death penalty for traffickers. While these laws are intended to curb drug abuse, they have created a regulatory bottleneck for legitimate medical use.
To prescribe an opioid, a doctor must navigate a complex web of approvals from the National Agency of Drug and Food Control (BPOM), the Ministry of Health, and the National Narcotics Board (BNN). Prescriptions are tightly regulated, and even when written, the drugs are often unavailable in pharmacies and hospitals outside major cities like Jakarta and Surabaya. The result: a patient in a rural area with terminal cancer may have no access to morphine at all.
The Fear Factor: Why Doctors Hesitate
The most insidious barrier is fear. Surveys and qualitative studies reveal that Indonesian physicians are deeply afraid of legal prosecution, professional sanctions, and social stigma if they prescribe opioids—even for legitimate medical use. This fear is not irrational. The BNN, a powerful agency, often frames all opioids as dangerous, and the government has publicly emphasized the risks of addiction and misuse.
Doctors worry that a prescription could be misconstrued as drug trafficking, leading to criminal charges. They fear that a patient’s family might report them, or that they could be targeted by anti-drug operations. As a result, many choose to avoid opioids altogether, leaving patients to suffer in silence.
The Human Cost: Patients Left in Agony
The impact on patients is devastating. Indonesia has a significant cancer burden, with hundreds of thousands of new cases each year, many diagnosed at late stages when pain is severe. Yet, palliative care services are extremely limited, concentrated in a few teaching hospitals. Most of the archipelago has no access to specialized pain management.
For those who do receive a prescription, the supply chain is unreliable. Morphine is cheap—a month’s supply can cost under $10—but the systemic barriers make it effectively inaccessible. Some patients resort to the black market, risking legal consequences, while others simply endure the pain, often guided by cultural norms that valorize patience (“sabar”) over seeking relief.
The Policy Imbalance: A Treaty Betrayed
Indonesia is a signatory to the 1961 Single Convention on Narcotic Drugs, which obligates states to both prevent drug abuse and ensure adequate availability of controlled substances for medical purposes. In practice, however, the government has prioritized control over access, creating what experts call a “policy imbalance.”
This imbalance is not unique to Indonesia, but it is particularly acute. The country’s zero-tolerance approach to illicit drugs, reinforced by high-profile executions of traffickers, has created a climate where all opioids are viewed with suspicion. The BNN’s powerful presence and public campaigns have shaped a narrative that these drugs are inherently dangerous, overshadowing their medical necessity.
Breaking the Cycle: The Way Forward
Addressing this crisis requires a multi-pronged approach. First, the government must recognize that access to pain relief is a human right and a medical necessity. This means implementing the dual mandate of the Single Convention more faithfully, ensuring that control measures do not impede legitimate medical use.
Second, doctors need protection and education. Clear guidelines, safe harbor provisions, and training in pain management can help alleviate their fears. The medical community must advocate for a balanced approach that treats opioids as essential medicines, not just threats.
Third, public awareness is crucial. Cultural attitudes that equate pain with virtue must be challenged. Patients and families should know that untreated pain is not inevitable and that palliative care can dramatically improve quality of life.
Finally, the supply chain must be strengthened. This includes simplifying procurement processes, ensuring availability in rural areas, and investing in palliative care infrastructure. International organizations and NGOs can support these efforts by sharing best practices and providing technical assistance.
Conclusion
The pain paradox in Indonesia is a tragedy of misplaced priorities. While the government’s fear of drug abuse is understandable, it has led to a situation where millions suffer needlessly. By rebalancing policy, protecting doctors, educating the public, and strengthening the healthcare system, Indonesia can honor its international commitments and, more importantly, its duty to its citizens. No one should have to endure unbearable pain when safe, effective, and affordable relief exists.
Summary
- Indonesia’s medical opioid consumption is among the lowest globally, despite a significant disease burden and international treaty obligations.
- Strict narcotics laws and regulatory hurdles create a bottleneck that makes it nearly impossible for patients to access pain relief.
- Doctors fear legal prosecution and stigma, leading to widespread reluctance to prescribe opioids even for legitimate medical use.
- Palliative care services are scarce, and morphine is often unavailable outside major cities, leaving patients to suffer or turn to the black market.
- A policy imbalance prioritizes control over access, but a balanced approach—with legal protections, education, and supply chain improvements—could change this.
FAQ
Q: Why is medical opioid access so low in Indonesia?
A: The low access is due to a combination of strict narcotics laws, regulatory bottlenecks, fear among doctors, and a lack of palliative care infrastructure. These factors create a system where even essential medicines like morphine are difficult to prescribe and obtain.
Q: What are the consequences for patients?
A: Patients with terminal illnesses or severe chronic pain often suffer untreated pain, which can lead to physical and psychological distress. Some may resort to illegal sources, risking legal penalties, while others endure pain without relief.
Q: Is the Indonesian government aware of this issue?
A: Yes, but the government has prioritized drug control over access, reflecting a broader global trend. However, there is growing advocacy from medical professionals and international organizations to address this imbalance.
Q: What can be done to improve access?
A: Solutions include policy reforms to simplify prescribing, legal protections for doctors, training in pain management, public education to reduce stigma, and strengthening the supply chain to ensure availability in all regions.
Q: Is morphine expensive?
A: No, morphine is relatively cheap—a month’s supply can cost under $10. The barriers are not financial but systemic, involving regulation, distribution, and professional reluctance.
Leave a Reply